Chicoric Acid Ameliorates Nonalcoholic Fatty Liver Disease via the AMPK/Nrf2/NFκB Signaling Pathway and Restores Gut Microbiota in High-Fat-Diet-Fed Mice

Xiaoqin Ding,1 Tunyu Jian,1 Jiawei Li,1 Han Lv,1 Bei Tong,1 Jing Li,2 Xiuhua Meng,1 Bingru Ren,1 and Jian Chen1,2

1Institute of Botany, Jiangsu Province and Chinese Academy of Sciences, Nanjing 210014, China
2Department of Food Science and Technology, College of Light Industry and Food Engineering, Nanjing Forestry University, Nanjing 210037, China

Correspondence should be addressed to Jian Chen; chenjian80@aliyun.com

Received 1 July 2020; Revised 29 September 2020; Accepted 8 October 2020; Published 4 November 2020

Academic Editor: Massimo Collino

Copyright © 2020 Xiaoqin Ding et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This study examines the effects of chicoric acid (CA) on nonalcoholic fatty liver disease (NAFLD) in high-fat-diet- (HFD-) fed C57BL/6 mice. CA treatment decreased body weight and white adipose weight, mitigated hyperglycemia and dyslipidemia, and reduced hepatic steatosis in HFD-fed mice. Moreover, CA treatment reversed HFD-induced oxidative stress and inflammation both systemically and locally in the liver, evidenced by the decreased serum malondialdehyde (MDA) abundance, increased serum superoxide dismutase (SOD) activity, lowered in situ reactive oxygen species (ROS) in the liver, decreased serum and hepatic inflammatory cytokine levels, and reduced hepatic inflammatory cell infiltration in HFD-fed mice. In addition, CA significantly reduced lipid accumulation and oxidative stress in palmitic acid- (PA-) treated HepG2 cells. In particular, we identified AMPK as an activator of Nrf2 and an inactivator of NFκB. CA upregulated AMPK phosphorylation, the nuclear protein level of Nrf2, and downregulated NFκB protein level both in HFD mice and PA-treated HepG2 cells. Notably, AMPK inhibitor compound C blocked the regulation of Nrf2 and NFκB, as well as ROS overproduction mediated by CA in PA-treated HepG2 cells, while AMPK activator AICAR mimicked the effects of CA. Similarly, Nrf2 inhibitor ML385 partly blocked the regulation of antioxidative genes and ROS overproduction by CA in PA-treated HepG2 cells. Interestingly, high-throughput pyrosequencing of 16S rRNA suggested that CA could increase Firmicutes-to-Bacteroidetes ratio and modify gut microbial composition towards a healthier microbial profile. In summary, CA plays a preventative role in the amelioration of oxidative stress and inflammation via the AMPK/Nrf2/NFκB signaling pathway and shapes gut microbiota in HFD-induced NAFLD.

1. Introduction

Nonalcoholic fatty liver disease (NAFLD), characterized by hepatic fat accumulation in patients without consumption of excessive alcohol, is the manifestation of metabolic syndrome in the liver. NAFLD ranges from simple hepatic steatosis to steatohepatitis (NASH), fibrosis, and cirrhosis [1]. The prevalence of NAFLD is increasing rapidly worldwide, which has become the major cause of chronic liver disease consistent with the increasing incidence of obesity [2]. The underlying mechanism in the development of NAFLD is complicated. The increase of free fatty acid (FFA) levels could cause fat accumulation, along with consequent oxidative stress and insulin resistance to activate proinflammatory cytokine production and release systemically and locally in the liver [3]. Hepatic oxidative stress and inflammation have been revealed to play critical roles in the progression of NAFLD in recent studies [3, 4]. It is reported that anti-inflammatory therapy can effectively improve the NAFLD/NASH [5]. Besides, gut microbiota was also considered to play an important role in the pathophysiology of NAFLD, through the gut-liver axis [6].

Adenosine monophosphate-activated protein kinase (AMPK) has been proposed to be a potential therapeutic...
mice exhibited a significant level \((p < 0.001)\). In addition, compared with the ND mice, serum total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C) levels were significantly increased, and high-density lipoprotein cholesterol (HDL-C) level was decreased in the HFD mice \((p < 0.001)\), while CA administration significantly downregulated TC, TG, and LDL-C levels, as well as upregulated HDL-C level \((p < 0.001)\). Furthermore, the serum levels of interleukin-1 (IL-1), IL-6, IL-1β, and tumor necrosis factor-α (TNF-α) were all increased in the HFD group in comparison with the ND group \((p < 0.001)\). Consequently, CA \((15 \text{ and } 30 \text{ mg/kg})\) administration led to the reduction of IL-2 \((p < 0.01)\), IL-6 \((p < 0.001)\), IL-1β \((p < 0.001)\), and TNF-α \((p < 0.01, p < 0.05)\). These results suggested that CA could ameliorate HFD-induced hyperglycemia, dyslipidemia, and inflammation in mice.

2.2. CA Alleviated Hepatic Lipid Accumulation, Oxidative Stress, and Liver Injury in Mice Fed with a High-Fat Diet.

Lipid accumulation in the liver is a sign of NAFLD. As observed in Figure 2(a), Oil Red O- (ORO-) stained lipid droplets were more prominent in sections from the HFD mice in comparison with those of the ND mice, while CA-treated mice had a relative healthier liver tissue \((p < 0.001)\). Moreover, large areas of steatosis, cytoplasmic vacuolation (red arrow), and inflammatory cell infiltration (black arrow) were seen in hepatic hematoxylin and eosin (H&E) staining of the HFD mice; all of which were ameliorated after CA treatment \((p < 0.001)\). As showed in Figure 2(f), dihydroethidium (DHE) staining of the liver in HFD mice established a distinct higher in situ ROS in comparison with the ND mice \((p < 0.001)\). However, both two doses of CA treatment notably restored ROS overproduction in the liver \((p < 0.001)\). Furthermore, the enzymatic activities of serum pyruvic transaminase alanine aminotransferase (GPT-ALT) and glutamic oxaloacetic transaminase aspartate aminotransferase (GOT-AST) were dramatically increased in HFD mice \((p < 0.001)\). These two markers of liver injury were both reversed after CA treatment \((p < 0.01, p < 0.001)\). All above data suggested that CA could ameliorate HFD-induced lipid accumulation, oxidative stress, and liver injury.

2.3. CA Suppressed the Hepatic Nrf2 Pathway and Liver Inflammation in HFD Mice.

The inflammatory reaction is one of the major features of liver injury in NAFLD \([23]\). To determine whether CA could inhibit hepatic inflammatory responses in NAFLD, we assessed the hepatic levels of inflammatory cytokines. As showed in Figure 3(a), the hepatic levels of inflammatory cytokines were all increased in the HFD group in comparison with the ND group.
Consequently, CA administration reduced IL-2 ($p < 0.001$), IL-6 ($p < 0.01, p < 0.001$), IL-1β ($p < 0.01$), and TNF-α ($p < 0.05, p < 0.05$) levels in the liver. As a transcription factor that plays a crucial role in inflammation, NFκB can facilitate the occurrence and development of NAFLD [24]. In parallel with the elevated levels of these inflammatory factors.
cytokines, the hepatic protein expression levels of p-IKKα/β (p < 0.01), p-IκBa (p < 0.01), and p-NFκB (p < 0.001) were all significantly increased in HFD mice in comparison with those of ND mice, while CA administration led to a remark-
able reduction of these parameters (Figure 3(b); p < 0.01). These findings demonstrated the significant anti-
inflammatory effect of CA in NAFLD.

2.4. CA Ameliorated Lipid Accumulation and Oxidative Stress and Inhibited the NFκB Pathway in PA-Treated HepG2 Cells.

To further investigate the role of CA in the amelioration of
NAFLD, we constructed an in vitro NAFLD model by using
HepG2 cells as previously described [25]. As shown in
Figure 4(a), there was no significant growth inhibition of
HepG2 cells after CA treatment even up to the concentration
of 250 μM, indicating the well safety of CA. Significantly
more lipid droplets were observed in PA-treated HepG2 cells
than those of the normal group (Figure 4(b); p < 0.001). And
the results showed that the intracellular TC and TG levels
were significantly increased in PA-treated HepG2 cells in
comparison with the normal group (Figure 4(c); p < 0.001).
Interestingly, the accumulation of lipids induced by PA treat-
ment was significantly decreased by CA (10 and 20 μM)
administration (p < 0.01, p < 0.001). As showed in
Figure 4(d), using DHE and MitoSOX Red staining, we
observed that CA reduced the intracellular O$_2^−$ and mito-
chondrial oxidative stress in PA-treated HepG2 cells
(p < 0.001). To further confirm the antioxidiant effect of CA
in NAFLD, we assessed intracellular ROS through the 2′,7′-
dichlorofluorescein diacetate (DCFH-DA) detector. PA
treatment significantly elevated ROS production in HepG2
cells, but it was prevented after CA administration
(Figure 4(e); p < 0.001). In addition, the protein levels of p-
IKKα/β (p < 0.01), p-IκBa (p < 0.001), and p-NFκB
(p < 0.01) were significantly increased in PA-treated HepG2
cells, which were remarkably decreased after CA administra-
tion (Figure 4(f); p < 0.01, p < 0.001). These data suggested
the lipid regulation, antioxidiant activity, and the inhibition
of the NFκB pathway of CA in vitro evaluation.

2.5. CA Activated Keap1/Nrf2 Signaling Both in the Liver of
HFD Mice and PA-Treated HepG2 Cells. The keap1/Nrf2
pathway is one of the most important defense mechanisms
against oxidative stress. It has been shown that Nrf2$^{-/-}$ mice
fed with a high-carbohydrate diet failed to induce antioxidiant
enzymes resulting in oxidative liver damage [26]. In the pre-
sent study, high keap1 protein level (p < 0.01) and low nuclear
Nrf2 protein level (p < 0.001) were both observed in the liver
of HFD mice. In accordance with the inhibition of nuclear
Nrf2, significant decreases of protein levels of HO-1
(p < 0.001), SOD1 (p < 0.01), and SOD2 (p < 0.001) were also
detected in the liver of HFD mice in comparison with those
in ND mice. However, treatment with CA significantly
decreased keap1 protein expression level (p < 0.05), upregu-
lated nuclear Nrf2 protein level (p < 0.001, p < 0.01), and
increased the protein levels of HO-1 (p < 0.01, p < 0.001),
SOD1 (p < 0.001, p < 0.01), and SOD2 (p < 0.01) in the liver
of mice fed with a high-fat diet (Figure 5(a)). In accordance
with the suppression of keap1/Nrf2 signaling in the liver of
HFD mice, we also observed the elevated keap1 (p < 0.05),
downregulated nuclear Nrf2 (p < 0.001), and decreased
HO-1 (p < 0.05), SOD1 (p < 0.001), and SOD2 (p < 0.05)
protein levels in PA-treated HepG2 cells, and all of these
parameters were reversed to normal after CA administration
(Figure 5(b)).

2.6. CA Suppressed Oxidative Stress and Inflammation via
AMPK Activation. AMPK is a key energy sensor of cellular
metabolism, including oxidative stress and inflammation
[27, 28]. Both in the liver of HFD mice and PA-treated
HepG2 cells, decreased AMPK phosphorylation at threonine
183/172 levels (p < 0.01) could be observed in the present
study. However, the protein level of p-AMPK was signif-
ically elevated after CA administration both in vivo and
in vitro (Figures 6(a) and 6(b); p < 0.05, p < 0.01). To further
investigate whether CA activates keap1/Nrf2 and inhibits
NFκB via AMPK to suppress oxidative stress and inflamma-
tion in NAFLD, AMPK activator AICAR and AMPK inhibit-
or compound C were used as a pair in the CA-mediated
action of PA-treated HepG2 cells. The results showed that
AICAR (0.5 mmol/L) partly mimicked, while compound C
(CC, 10 μmol/L) partly ablished, the downregulative effect
of CA on keap1, the upregulative effect of CA on nuclear
Nrf2 protein level, and the downregulative effect of CA on
NFκB phosphorylation level in PA-treated HepG2 cells
(Figures 6(c)). These results suggested that the AMPK path-
way was involved in the CA-induced keap1-dependent activa-
tion of Nrf2 and suppression of NFκB in PA-treated
HepG2 cells.

Moreover, both AICAR and CC were used to investigate
whether the AMPK pathway was also involved in the CA-
mediated antioxidiant effect in PA-treated HepG2 cells. Our
data showed that AICAR partly mimicked, while compound C
(CC, 10 μmol/L) partly abolished the downregulative effect of CA on ROS pro-
duction in PA-treated HepG2 cells (Figure 6(d)). In
addition, the Nrf2 inhibitor ML385 (5 μM) partly blocked the
upregulation of SOD1, SOD2, and HO-1 and the downregulation of ROS production by CA in PA-
induced HepG2 cells. These results indicate Nrf2 as a key fac-
tor in the regulation of oxidative stress by CA. Likewise, we
investigated whether ML385 blocked the role of CA-
mediated NFκB inactivation. The result showed that ML385
diminished CA-induced NFκB suppression, suggesting that
Nrf2 plays a key role in CA-mediated amelioration of inflam-
amation (Figures 6(e) and 6(f)).

All these data above demonstrated that CA might sup-
press oxidative and inflammation via AMPK-mediated
keap1/Nrf2 activation and NFκB inhibition in NAFLD.

2.7. CA Shaped the Gut Microbiota in HFD Mice. Gut micro-
biota dysbiosis has been repeatedly observed in NAFLD and
NASH [29]. To reveal the possible contribution of gut micro-
bioita in the therapeutic action of CA, we analyzed the fecal
microbiota composition using the 16S rRNA pyrosequencing
based on V3-V4 region. After size filtering, quality control,
and chimera removal, we totally detected 1953854 raw tags
from 24 fecal samples with 1953854 clean sequences for fur-
ther analysis, from which were clustered into operational
taxonomic unit (OTU) with similarity higher than 97%. According to the rarefaction curve analysis (Figure 7(a)), the OTU rarefaction curves reached a steady level, indicating that the libraries were large enough to obtain the major information of the bacterial diversity in all samples. A Venn diagram displaying 593 OTUs was shared among 3 groups, and each group owned unique OTUs (Figure 7(b)). Alpha analyses with chao1 (p < 0.05), observed_species, PD_whole_tree, and Shannon indexes indicated that the HFD mice had decreased microbial species richness, while CA administration increased the diversity of gut bacteria (Figures 7(c) and 7(d)). The nonmetric multidimensional scaling (NMDS) analysis and principal component analysis (PCA) revealed a separated clustering of gut microbiota among ND, HFD, and CA-treated mice (Figures 7(e) and 7(f)).

The microbial community bar plot analyses on top phylum and genus levels exhibited different bacterial community structures among the groups. The microbial community structure at phylum level was dominated by **Firmicutes** and **Bacteroidetes**. The increased level of the phylum **Firmicutes** and decreased level of the phylum **Bacteroidetes** were observed in HFD mice, which were reversed by CA administration (Figure 8(a)). Thus, **Firmicutes**-to-**Bacteroidetes** ratio (F/B ratio) was significantly increased (p < 0.01) in the HFD group compared with the ND group, and after CA administration, this ratio was significantly decreased (Figure 8(b); p < 0.05). Among the dominant microbial communities at the genus level, the relative abundance of **Lactobacillus** (p < 0.05), **Turicibacter** (p < 0.05), **Bacteroides**, **Faecalibaculum** (p < 0.001), and **Candidatus_Saccharimomas** was higher, while the proportion of **Lachnospiraceae**, **Allobacter**, **Ruminococcaceae_UGC-014**, and **Alloprevotella** was decreased in HFD mice compared with the ND mice. However, CA administration reversed the proportion of **Lactobacillus** (p < 0.05), **Turicibacter** (p < 0.05), **Ruminococcaceae_UGC-014**, **Alloprevotella**, and **Candidatus_Saccharimomas** in HFD mice (Figure 8(c)). The community heat map analysis confirmed these changes (Figure 8(d)). All these suggested that CA enhanced the diversity of gut microbiota and restored the alert microbiota to a state more similar to ND mice.

3. Discussion

Oxidative stress, inflammatory response, and gut microbiota are critical factors in the progression of NAFLD. Due to its potential antioxidant and anti-inflammatory activities, CA may contribute to the intervention of NAFLD. In the present study, we evaluated the effects of CA treatment on NAFLD both in HFD mice and PA-induced HepG2 cells. The amelioration of oxidative stress and inflammation was observed. Moreover, CA greatly shaped the composition of gut microbiota into a status more similar to ND mice. Collectively, the therapeutic effect of CA on NAFLD has been proven through the present investigation.

As an important cellular sensor to restore cellular energy homeostasis and a central regulator of multiple metabolic pathways, AMPK has been proposed as a therapeutic target for metabolic diseases [7, 30, 31]. The ability to control the energy balance equation through defined metabolic pathways heavily pursues AMPK as a golden target against obesity [31]. Activation of AMPK by the E3 ubiquitin ligase makerin finger protein 1 (MKRN1) represses diet-induced metabolic syndrome [8]. Lipid metabolism abnormal and insulin resistance are two typical features of NAFLD, so the regulative effects of lipid and glucose metabolism of AMPK have got the most attention in NAFLD. Liver-specific reduction of AMPK activity inhibits acetyl-CoA carboxylase (ACC) phosphorylation and leads to lipogenesis increases in hepatocytes [9]. Liver AMPK activator PF-06409577 decreases both hepatic and systemic lipids in the high-fat-diet-induced NAFLD models of the rodent and monkey preclinical models [32]. Activation of AMPK suppresses hepatic glucose release and enhances insulin sensitivity in dexamethasone-induced fatty liver disease in C57BL/6 mice [33]. In this study, the
reduction of AMPK phosphorylation was observed both in the liver of HFD mice and PA-treated HepG2 cells, in company with elevated body weight, serum glucose, and lipid metabolism disorders. It has been surmised that numerous polyphenols are capable of activating AMPK via the elevation of AMP levels by inhibiting mitochondrial ATP production, which serves as indirect AMPK activators [34]. CA has been found to restore insulin signaling and dyslipidemia [19, 35]. Our results indicated that CA alleviated HFD-induced hyperglycemia and dyslipidemia, as well as reduced lipid accumulation in the liver. In addition to these, CA could also restore PA-induced lipid drop deposition and decrease TC and TG levels in HepG2 cells. Importantly, decreased AMPK phosphorylation levels in the liver of HFD mice and PA-treated HepG2 cells were both reversed by CA.

Moreover, oxidative metabolism also contributes to oxidative stress and inflammation during NAFLD [36]. Recent researches demonstrated that suppression of oxidative stress and inflammation contributed to the amelioration of NAFLD or NASH [5, 37, 38]. Not only as a key sensor of energy balance but also a factor of redox balance improvement and inflammation reduction, the antioxidation and anti-inflammatory effect of AMPK activation has gained more attention [39, 40]. Activation of AMPK could alleviate mitochondrial oxidative damage and apoptosis [40]. AMPK was also reported to prevent oxidative stress-induced senescence by improving autophagic flux and NAD(+) homeostasis [41]. Furthermore, stimulation of AMPK phosphorylation prevented HFD-induced insulin resistance and inflammation in adipose tissue through anti-inflammatory effects in obesity and attenuated lipopolysaccharide-induced secretion of pro-inflammatory cytokines such as TNF-α and MCP-1 [11]. In this study, we observed oxidative stress and inflammation, including elevated MDA and suppressed SOD activity in HFD mice, overproduction of O2− in the liver and ROS in PA-treated HepG2 cells, and increased serum IL-2, IL-6, IL-1β, and TNF-α levels in HFD mice. It has been noted that the antioxidant and anti-inflammatory effects of CA have already been documented in metabolic diseases, including obesity and atherosclerosis [16, 42]. Consistent with these reports, in our experiments, CA treatment dramatically decreased ROS production and inflammatory cytokines. Taken together, our data demonstrated that CA could mitigate high-fat-induced inflammation and oxidative damage.

**Figure 3:** CA suppressed the hepatic NFκB pathway and liver inflammation in HFD mice. (a) Hepatic levels of IL-2, IL-6, IL-1β, and TNF-α (n = 8). (b) Hepatic p-IKKα/β, p-IκBα, and p-NFκB protein levels in mice (n = 3). Data represent the mean ± SEM. **p < 0.01 and +++p < 0.001 vs. ND group. *p < 0.05, **p < 0.01, and ***p < 0.001 vs. HFD group.
Figure 4: Continued.
in vivo and in vitro probably via AMPK phosphorylation activation.

Importantly, those benefits of antioxidative and anti-inflammation were also observed in previous studies on Nrf2 activation [43–45]. Keap1/Nrf2 system forms the cellular defense against oxidative and electrophilic stresses, which has been known to attenuate inflammation [44, 45]. Activation of Nrf2 has also been confirmed to reduce hepatic lipid accumulation in bisphenol A-induced mouse model of NAFLD [46]. It has been demonstrated that Nrf2-dependent antioxidant genes contain almost all the antioxidant enzymes, including SOD, catalase, glutathione S-transferase (GST), glutathione peroxidase-1 (GPX-1), and HO-1 [47]. Activation of Nrf2 in hepatocytes inhibited inflammatory and oxidative stress, suppressed hepatic steatosis, and mitigated liver fibrosis in NASH [48, 49], while inactivation of Nrf2 led to aggravation of liver injury in NASH; thus, impairment of Nrf2 activity represented a major risk factor for the evolution of NAFLD to NASH [50]. We surmised that activation of Nrf2 functions attributed to ROS elimination in NAFLD. Likewise, we observed keap1 and Nrf2 alteration both in the liver of HFD mice and PA-treated HepG2 cells. Activation of Nrf2 by CA increased the expression of downstream antioxidant genes, including SOD1, SOD2, and HO-1, thereby functionally attenuated hepatocyte injury in vivo and in vitro. What is interesting, recent researches have revealed the crosstalk between AMPK and Nrf2 [14, 39, 51]. Nrf2 signaling was revealed as the downstream signal of AMPK in oxidative stress and inflammation [39], and AMPK activation promotes autophagic degradation of keap1 to induce Nrf2 dissociate from keap1 and translocate to the nucleus [52]. However, whether Nrf2 is the downstream signal of AMPK in HFD-induced NAFLD still remains unclear. To confirm the crosstalk between AMPK and Nrf2 in NAFLD and whether CA could regulate Nrf2 via AMPK, we conducted AMPK activator AICAR and inhibitor compound C in PA-induced HepG2 cell. Our results showed that both PA-induced elevation of keap1 and reduction of nuclear Nrf2 protein level and ROS overproduction in HepG2 cells were reversed by either CA or partly reversed by AMPK activator AICAR. Importantly, the downregulative effect on keap1 level and upregulative effect on Nrf2 level of CA and the decrease of ROS production were partly eliminated by adding AMPK inhibitor compound C. These results indicated that the AMPK pathway was involved in the keap1-dependent regulation of CA on Nrf2 level in PA-treated HepG2 cells. Likewise, the upregulative effect on SOD1, SOD2, and p-NFkB protein levels, and the downregulative effect of ROS production of CA were partly diminished by Nrf2 inhibitor ML385. These results further indicated that Nrf2 was involved in CA-mediated amelioration of oxidative stress in PA-treated HepG2 cells.

On the one hand, inflammation results in a stress response of hepatocytes and may lead to lipid accumulation and precede steatosis [53]. On the other hand, increased FFA levels, insulin resistance, and adipose tissue dysfunction activate the production and release of proinflammatory cytokines, both systemically and locally in the liver [3]. NFkB has been recognized as a key proinflammatory transcription factor in inflammation and immune response. Persistent NFkB pathway activation has been shown in animal models or patients with...
NAFLD and NASH [54–57]. To further characterize the mechanism of inhibitory effect of CA on inflammatory cytokine production, we investigated the effect of CA on the NFκB pathways and serum inflammatory cytokines in HFD mice. It was well noted that the increase of serum IL-2, IL-6, IL-1β, and TNF-α was confirmed in HFD mice, as well as the inflammatory cell infiltration detected by liver H&E staining. CA treatment significantly downregulated inflammation systemically and in the liver. Studies have shown that the NFκB pathway could be regulated by AMPK and Nrf2 [15, 58]. Herewith, we showed many degrees of upregulation on NFκB phosphorylation by AICAR in PA-treated HepG2 cells. Moreover, the upregulatory effect of CA on NFκB phosphorylation level was partly eliminated by compound C. Similarly, the suppression on p-NFκB of CA was partly diminished by ML385. These results indicated that the AMPK-Nrf2 pathway was involved in the regulation of CA on NFκB suppression in PA-treated HepG2 cells.

Growing evidences indicate the gut microbiota alteration in metabolic disorders, including NAFLD [29]. In the present study, the composition and proportion of gut microbiota were changed in HFD mice. Our 16S rRNA sequencing experiment revealed that CA treatment increased the OTU numbers and upregulated chao1, observed_species, PD_whole_tree, and Shannon indexes in HFD mice. Based on the NMDS and PCoA, HFD changed the overall gut microbiota composition in NAFLD mice, and it was reversed by CA treatment. Bacteroidetes and Firmicutes are two dominant bacterial divisions in the gut, and numerous studies have observed that the ratio of Firmicutes to Bacteroidetes in gut microbiota, characteristic of “obese microbiota”, was associated with metabolic disorders including obesity and NAFLD [22, 59, 60]. In the current study, HFD induced relative increase of Firmicutes and decrease of Bacteroidetes in the gut in comparison with the ND mouse group, causing the significantly elevation of F/B ratio, in parallel with body weight gain and adiposity in HFD mice. CA treatment significantly

**Figure 5:** CA regulated keap1/Nrf2 signaling in the liver of HFD mice and PA-treated HepG2 cells. (a, b) The protein levels of keap1, nuclear Nrf2, SOD1, SOD2, and HO-1 in the liver or HepG2 cells. Data represent the mean ± SEM, n = 3 per group. ++p < 0.01 and +++p < 0.001 vs. ND or normal group. ∗∗p < 0.01 and ∗∗∗p < 0.001 vs. HFD or PA group.
Figure 6: Continued.
reversed F/B ratio in HFD mice, as well as decreased HFD-induced body weight gain and adiposity. Although *Lactobacillus* is recognized as a probiotic bacterium in metabolic disorders including NAFLD, some studies showed the contrary results [61–63]. Elevated *Lactobacillus* in the gut may correlate with decreased insulin sensitivity and increased plasma inflammatory cytokine [61]. Similar increase of *Lactobacillus* was also observed in NAFLD patient and mice [62, 63]. Furthermore, some species of *Lactobacillus* such as *L. reuteri* also had a redundant role associated with increased body fat and insulin levels [64]. In the current study, the proportion of *Lactobacillus* was increased almost 3 folds (from 5.3% to 14%) in HFD mice in comparison of ND mice and lowered to 6.1% after CA administration. NAFLD severity associates

![Figure 6: CA suppressed oxidative stress and inflammation via AMPK activation. (a, b) Effects of CA on the phosphorylation of AMPK in the liver and HepG2 cells (n = 3). (c) The protein levels of keap1, nuclear Nrf2, and p-NFκB in HepG2 cells (n = 3). (d) ROS production of cells detected by DHE staining (scale bar: 100 μM) and the fluorescence intensity analysis (n = 4). (e) The protein levels of SOD1, SOD2, HO-1, and p-NFκB in HepG2 cells (n = 3). (f) ROS production in HepG2 cells detected by DCFH-DA detector (n = 8). Data represent the mean ± SEM. ++p < 0.01 and +++p < 0.001 vs. ND or normal group. *p < 0.05 and **p < 0.01 vs. HFD or PA group.](image)

with gut dysbiosis and a shift in metabolic function of the gut microbiota. We conjectured that overmuch or disproportionate *Lactobacillus* might cause adverse reactions. *Bacteroides* abundance was significantly increased in NASH and has been defined as independently associated with NASH [65]. In this study, *Bacteroides* was increased in the HFD group, indicating the high severity of NAFLD in the mice. *Turicibacter*, a genus of the *Firmicutes* phylum *Firmicutes*, has been primary confirmed to alter gut microbiota of healthy and be associated with hyperlipidemia and body gain [66]. Compared with the HFD group, the abundance of *Turicibacter* was decreased in the CA group. *Faecalibaculum* belonging to *Erysipelotrichaceae*, enriched in HFD mice, was closely related to adiposity.
Figure 7: Continued.
correlated with oxidative stress [67]. In this study, the amount of *Faecalibaculum* was increased in HFD mice and reversed to normal after CA administration. CA also contributed to an increase in the abundance of *Alloprevotella*, which was associated with health benefits in short-chain fatty acids producing and anti-inflammatory [68]. We primary infer that the amelioration of NAFLD by CA may be associated with the alleviation on the dysbiosis of gut microbial, and further investigation is needed to support this hypothesis.

We noticed that previous studies also tried to explore the therapeutic effect of CA on NAFLD or NASH, and many researches had been well done. Using methionine and choline deficiency-induced mouse model and cell models, Kim et al. revealed the improvement of NASH by CA [69]. Xiao et al. placed emphasis on the antiobesity effect of CA by the regulation of COX-2, p-JNK, PPARγ, and C/EBPα in high-fat-diet mice [70]. Here, using high-fat-diet-induced NAFLD mouse model and PA-induced cell model, we focused on the antioxidant and anti-inflammation effect of CA and tried to connect and explain the crosstalk among AMPK, keap1/Nrf2, and NFκB system in HFD-induced NAFLD for the first time. These results of the study formed a completed signal path loop, which clearly figured out the mechanism of CA on HFD-induced NAFLD. Additionally, we applied high-throughput pyrosequencing of 16S rRNA to observe the changes of related gut microbial composition, and the results suggested that high-fat-diet-induced decrease of *Firmicutes*-to-*Bacteroidetes* ratio and dysbiosis of NAFLD mice could be reversed by CA treatment. Ziamajidi et al. observed that chicory seed extract improved diabetes- and oleic acid-induced NAFLD and NASH by PPARα and SREBP-1 [20]. Chicory seed extract contains a variety of compounds, yet the precise ingredient is not clear. Here, in this study, we confirmed the amelioration of NAFLD by CA, as a single active compound. Mohammadi et al. paid the attention on the improvement of lipid accumulation by CA and fish oil through a NAFLD cell model via the AMPK-mediated SREBP-1/FAS and PPARα/UCP2 pathways [71]. Here, we investigated the improvement of oxidative stress and inflammation in both NAFLD animal and cell models via the AMPK/Nrf2/NFκB pathway and this might be associated with the restored gut microbiota. The pathogenesis of NAFLD is very complex, and CA may serve as a multitargeting pharmacologically active compound. Combined with these previous studies, CA would be an attractive agent for the amelioration of NAFLD.

In conclusion, CA treatment displays an effect against lipid dysregulation, oxidative stress, inflammation, and gut microbiota in NAFLD. The action of CA in upregulating AMPK phosphorylation and nuclear Nrf2 level, as well as suppression of NFκB in hepatocytes, may contribute to the protective effect of the liver in NAFLD. It is conceivable that CA may be able to protect hepatocytes from oxidative damage and inflammation via regulating AMPK-mediated Nrf2 activation and NFκB inactivation and shaping gut microbiota. Our findings provide strong scientific basis of CA for amelioration of NAFLD and its related metabolic diseases.

### 4. Materials and Methods

#### 4.1. Reagents and Chemical.

CA (purity > 98%), palmitic acid, and fatty acid-free bovine serum albumin (BSA) were purchased from Nanjing Spring & Autumn Biological Engineering Corporation (Nanjing, China), Macklin (Shanghai, China), and YEASEN (Shanghai, China), respectively. AIA-CAR, Compound C, and ML385 were obtained from
Figure 8: Continued.
Beyotime Institute of Biotechnology (Haimen, China), Selleck (Houston, TX, USA), and MedChemExpress (NJ, USA), respectively. Dulbecco’s modified Eagle’s medium (DMEM), penicillin-streptomycin, and fetal bovine serum (FBS) were all obtained from Invitrogen-Gibco (Grand Island, NY). Cell Counting Kit-8 (CCK-8) assay and bicinchoninic acid (BCA) Protein Quantiﬁcation Kit were purchased from Biosharp (Hefei, China). Biochemical indexes including glucose, TC, TG, LDL-C, HDL-C, GPT-AST, and GOT-AST assay kits were purchased from Nanjing Jiancheng Bioengineering Institute (Jiangsu, China). MDA and SOD assay kits, DHE and DCFH-DA probes, and the nuclear protein extraction kit were obtained by Beyotime Institute of Biotechnology (Jiangsu, China). ORO staining kit was purchased from Nanjing Jiancheng Bioengineering Institute (Jiangsu, China). MitoSOX Red probe was obtained from Yeasen (Shanghai, jing Jiancheng Bioengineering Institute (Jiangsu, China). ORO staining kit was purchased from Nanjing Jiancheng Bioengineering Institute (Jiangsu, China). MDA and SOD assay kits, DHE and DCFH-DA probes, and the nuclear protein extraction kit were offered by Beyotime Institute of Biotechnology (Jiangsu, China). ORO staining kit was purchased from Nanjing Jiancheng Bioengineering Institute (Jiangsu, China). MitoSOX Red probe was obtained from Yeasen (Shanghai, China). Serum and hepatic inﬂammatory cytokines including IL-2 (EK202HS-96), IL-6 (EK206/3-96), IL-1β (EK201B/3-96), and TNF-α (EK282HS-96) enzyme-linked immunosorbent assay (ELISA) kits were purchased from MultiSciences (Lianke) Biotech Co., Ltd (Zhejiang, China). Antibodies against Nrf2, NFκB, p-NFκB, IkBα, p-IkBα, IKKβ, p-IKKα/β, and the HRP-linked secondary antibodies were obtained from Cell Signaling (Boston, MA, USA); antibodies against keap1, SOD1, and HO-1 were obtained from Santa Cruz Biotechnology (CA, USA); antibodies against SOD2 and AMPK were purchased from Proteintech Group (Chicago, USA). p-AMPK (T183/172) was purchased from Bioworld Technology (MN, USA).

4.2. Animal Model and the Treatment. All animal experiments were in strict accordance with the Guide for the Care and Use of Laboratory Animals approved by the Animal Ethics Committee of China Pharmaceutical University (cерetiﬁcate number: SYXX2016-0011, approval date: 27 January 2016 to 26 January 2021). Male C57BL/6 mice (20 to 25 g body weight) were housed with food and water available ad libitum in light, temperature, and humidity-controlled environments. The normal control group was fed with normal diet (ND), while the others were fed with HFD (18% lard stearin (w/w), 5% egg powder, 1% cholesterol, 20% sucrose, 0.1% bile salt, and 55.9% normal diet) [72] for 9 weeks. Then, the HFD mice received either CA (15 or 30 mg/kg/d, dissolved in water) or saline solution daily for 9 weeks by gavage (n = 8). Mice were sacriﬁced, and then the blood samples were collected from the carotid artery and centrifuged to obtain serum, and the livers were harvested for the following biochemical analysis. The serum and liver tissues were stored at -80°C.

4.3. Detection of Serum Biomarkers. The levels of serum glucose, TC, TG, LDL-C, HDL-C, MDA, SOD activity, GPT-AST, and GOT-AST were determined by commercial assay kits in accordance with the manufacturer’s instructions. The inﬂammatory cytokines including IL-2, IL-6, IL-1β, and TNF-α were measured using ELISA kits in accordance with the manufacturer’s instructions.

4.4. Histological Assessment. Pieces of the liver were ﬁxed in 4% paraformaldehyde and processed to parafﬁn wax then stained with hematoxylin and eosin (H&E). In addition, lipid droplets in the liver were observed by ORO staining in the frozen liver sections and quantiﬁed by ImageJ software. Histopathological changes of the livers were observed and photographed under a light microscope (Olympus, Tokyo, Japan).

4.5. Measurement of Hepatic Inﬂammatory Cytokines. Liver tissues were homogenized in lysis buffer (pH 7.2, Tris with 1% Triton X-100 and 0.1% protease inhibitor) and centrifuged at 12,000 g for 15 min. The supernatants were collected for determination of IL-2, IL-6, IL-1β, and TNF-α by ELISA.
kits according to the manufacturer’s instructions adjusted for protein content.

4.6. Cell Culture and Treatment. HepG2 cells were obtained from FuHeng Cell Center, Shanghai, China. Cells were cultured in low-glucose DMEM supplemented with 5% FBS and 1% penicillin-streptomycin and incubated at 37°C and 5% CO2. PA was dissolved in 50% ethanol by heating at 50°C, then conjugated with 10.5% fatty acid-free BSA (volume ratio 1:25) under agitation at 40°C for 2h, and finally diluted in culture media. HepG2 cells were pretreated with or without 250 μM PA for 24h and then incubated in the culture media with or without 250 μM PA or CA (10 and 20 μM, dissolved in PBS) for another 24h. To clarify the involved signaling pathways, AICAR (0.5 mM) or compound C (10 μM) was used to treat HepG2 cells.

4.7. Cell Viability Analysis. The cell viabilities were assessed using CCK-8 assay. In brief, HepG2 cells were plated into 96-well plates with 2×10^4 per well and incubated overnight. Afterwards, the cells were incubated with different concentrations (0-250 μM) of CA for 24h. Subsequently, CCK-8 working solution was added to each well and cultivated for another 1h. The absorbance was recorded on a microplate reader at 450 nm (Molecular Devices, Sunnyvale, USA).

4.8. Measurement of Lipid Uptake in HepG2 Cells. The cells were homogenized in lysis buffer. The intracellular TC and TG contents were measured using commercially assay kits according to the manufacturer’s instructions. The protein concentration was assayed using BCA protein quantitative kit. The intracellular TC and TG contents were presented as μmol/mg protein.

The lipid deposition in HepG2 cells was measured by ORO staining [73]. Briefly, after fixed in 4% formaldehyde for 15 min fixation and then cleaned with PBS, ORO working solution was injected into cells for 30 min. The cells were immediately washed with 60% isopropanol, incubated with hematoxylin for 5 minutes, washed by PBS and immediately imaged using microscopy (Olympus, Tokyo, Japan), and quantified by ImageJ software.

4.9. Detection of ROS. Liver in situ O2⋅− production was determined by fluorescence probe DHE labeling. Frozen liver sections were prepared for immediate DHE staining. Thawed sections were incubated with 2 μM DHE at 37°C for 30 minutes (avoiding light). After washed 3 times by PBS, sections were immediately imaged using fluorescence microscopy (Olympus, Tokyo, Japan) and quantified by ImageJ software.

Intracellular O2⋅− levels were detected using the DHE staining. Cells were incubated with PBS diluted DHE (10 μM) at 37°C for 20 min (avoiding light), washed with PBS for 3 times, and then imaged using fluorescence microscopy (Olympus, Tokyo, Japan). Mitochondrial ROS in HepG2 cells was measured by MitoSOX Red at a concentration of 4 μM for 20 min at 37°C, imaged using fluorescence microscopy (Olympus, Tokyo, Japan), and quantified by ImageJ software.

DCFH-DA fluorescent probe was used to detect intracellular ROS generation. Cells were washed with PBS after incubation with DCFH-DA (10 μM) at 37°C for 30 min (avoiding light). Fluorescence intensity was measured at 530 nm with an excitation wavelength of 485 nm using a fluorescence microscope (Tecan, Crailsheim, Germany).

4.10. Western Blot. The liver tissues and HepG2 cell cultures were lysed in RIPA buffer and then centrifuged again at 12,000 g for 15 min at 4°C, following the supernatant collection. The nuclear protein was obtained using a nuclear protein extraction kit. The concentration of protein was measured using a BCA protein assay kit, and then the protein level was normalized and the 5x loading buffer was added, following boiled at 100°C.

The proteins (equal amount) were electrophoresed on 10% SDS-PAGE at 85 V (stacking gel) and 135 V (separating gel), transferred onto a 2.2 μM PVDF membrane in a 4°C refrigerator at 300 mA for 1.5h, blocked with 5% skim milk for 2h at room temperature, and incubated with primary antibodies overnight at 4°C. The membranes were washed three times with TBST (8 min each time) and then probed with horseradish peroxidase- (HRP-) conjugated anti-rabbit or anti-mouse secondary antibody for 1h followed by six washes with TBST (8 min each time). The blot bands were visualized using enhanced chemiluminescence, and band intensities were analyzed using ImageJ gel analysis software. β-Actin and histone H3 were used as the loading controls.

4.11. Gut Microbiota Analysis. At the end of the intervention period, fresh fecal samples were collected and stored at -80°C immediately. The DNA of fecal samples was extracted using an EZNA Stool DNA kit (Omega Bio-tek, Norcross, GA, USA) according to the manufacturer’s instructions. Purity and quality of the genomic DNA were checked on 0.8% agarose gels. Amplification was performed targeting the variable regions V3-4 of bacterial 16S rRNA gene with the primers 338F (ACTTCTACGGGAGGCAGCAG) and 806R (GGAC TACHVGGGTWTCTAAT). The PCR was carried out on a Mastercycler Gradient (Eppendorf, Germany) in triplicate: 25 μL mixture containing 12.5 μL of KAPA 2G Robust Hot Start Ready Mix, 1 μL of forward primer (5 μM), 1 μL of reverse primer (5 μM), 5 μL of DNA sample (30 ng), and 5.5 μL of H2O. Cycling parameters were 95°C for 5 min, followed by 28 cycles of 95°C for 45 s, 55°C for 50 s, and 72°C for 45 s with a final extension at 72°C for 10 min. The PCR products were purified using a QIAquick Gel Extraction Kit (QIAGEN, Germany) and quantified using real-time PCR. Deep sequencing was performed at Beijing Allwegene Technology Inc. (Beijing, China) using Illumina Miseq PE300 sequencing platform (Illumina, San Diego, CA, USA) as described previously [74].

4.12. Statistical Analysis. All statistical analyses were performed using GraphPad Prism 8 (San Diego, CA). All data were expressed as the mean ± standard error of the mean (SEM). Statistical analysis was performed by one-way ANOVA analysis followed by Dunnett’s post hoc test. Statistical significance was set at p < 0.05.
Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflict of interest.

Authors’ Contributions

Xiaqin Ding and Tunyu Jian contributed equally to this work.

Acknowledgments

This study was supported by the grants from the National Natural Science Foundation of China (81973463, 82004018, and 32000279), the Open Fund of Jiangsu Key Laboratory for the Research and Utilization of Plant Resources (JSPKL2B202050), and the Jiangsu Agricultural Science and Technology Innovation Fund (CX(20)3167). Support was also received from the Jiangsu Scientific and Technological Innovations Platform named Jiangsu Provincial Service Center for Antidiabetic Drug Screening.

References

[1] G. Musso, M. Cassader, and R. Gambino, “Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies,” Drug Discovery, vol. 15, no. 4, pp. 249–274, 2016.

[2] Z. Younossi, Q. M. Anstee, M. Marietti et al., “Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention,” Gastroenterology & Hepatology, vol. 15, no. 1, pp. 11–20, 2018.

[3] E. Buzzetti, M. Pinzani, and E. A. Tschatzis, “The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD),” Metabolism, vol. 65, no. 8, pp. 1038–1048, 2016.

[4] I. R. Wanless and K. Shiota, “The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis,” Seminars in Liver Disease, vol. 24, no. 1, pp. 99–106, 2004.

[5] Y. Sumida and M. Yoneda, “Current and future pharmacological therapies for NAFLD/NASH,” Journal of Gastroenterology, vol. 53, no. 3, pp. 362–376, 2018.

[6] J. Aron-Wisnewsky, M. V. Warmbrunn, M. Nieuwdorp, and K. Clément, “Nonalcoholic fatty liver disease: modulating gut microbiota to improve severity?,” Gastroenterology, vol. 158, no. 7, pp. 1881–1898, 2020.

[7] E. A. Day, R. J. Ford, and G. R. Steinberg, “AMPK as a therapeutic target for treating metabolic diseases,” Trends Endocrinol. Metab., vol. 28, no. 8, pp. 545–560, 2017.

[8] M. S. Lee, H. J. Han, S. Y. Han et al., “Loss of the E3 ubiquitin ligase MKRN1 represses diet-induced metabolic syndrome through AMPK activation,” Nature Communications, vol. 9, no. 1, p. 3404, 2018.

[9] N. Dzamko, B. J. W. van Denderen, A. L. Hevener et al., “AMPK β1 deletion reduces appetite, preventing obesity and hepatic insulin resistance,” The Journal of Biological Chemistry, vol. 285, no. 1, pp. 115–122, 2009.

[10] C. Lyons and H. Roche, “Nutritional modulation of AMPK-impact upon metabolic-inflammation,” International Journal of Molecular Sciences, vol. 19, no. 10, p. 3092, 2018.

[11] T. W. Jung, H. S. Park, G. H. Choi, D. Kim, and T. Lee, “β-aminoisobutyric acid attenuates LPS-induced inflammation and insulin resistance in adipocytes through AMPK-mediated pathway,” Journal of Biomedical Science, vol. 25, no. 1, p. 27, 2018.

[12] C. R. Lindholm, R. L. Ertel, J. D. Bauwens, E. G. Schmuck, J. D. Mulligan, and K. W. Sauer, “A high-fat diet decreases AMPK activity in multiple tissues in the absence of hyperglycemia or systemic inflammation in rats,” Journal of Physiology and Biochemistry, vol. 69, no. 2, pp. 165–175, 2013.

[13] D. Garcia, K. Hellberg, A. Chaix et al., “Genetic liver-specific AMPK activation protects against diet-induced obesity and NAFLD,” Cell Reports, vol. 26, no. 1, pp. 192–208.e6, 2019.

[14] K. Zimmermann, J. Baldinger, B. Mayerhofer, A. G. Atanasov, V. M. Dirsch, and E. H. Heiss, “Activated AMPK boosts the Nrf2/HO-1 signaling axis—a role for the unfolded protein response,” Free Radical Biology & Medicine, vol. 88, Part B, pp. 417–426, 2015.

[15] J. D. Wardyn, A. H. Ponsford, and C. M. Sanderson, “Dissecting molecular cross-talk between Nrf2 and NF-κB response pathways,” Biochemical Society Transactions, vol. 43, no. 4, pp. 621–626, 2015.

[16] Q. B. Lu, M. Y. Wan, P. Y. Wang et al., “Chicoric acid prevents PDGF-BB-induced VSMC dedifferentiation, proliferation and migration by suppressing ROS/NFκB/mTOR/P70S6K signaling cascade,” Redox Biology, vol. 14, pp. 656–668, 2018.

[17] D. J. Lee and W. E. Robinson, “Human immunodeficiency virus type 1 (HIV-1) integrase: resistance to diketo acid integrase inhibitors impairs HIV-1 replication and integration and confers cross-resistance to L-chicoric acid,” Journal of Virology, vol. 78, no. 11, pp. 5835–5847, 2004.

[18] J. Lee and C. F. Scagel, “Chicoric acid: chemistry, distribution, and production,” Frontiers in Chemistry, vol. 1, p. 40, 2013.

[19] K. Ferrare, L. P. R. Bidel, A. Awwad et al., “Increase in insulin sensitivity by the association of chicoric acid and chlorogenic acid contained in a natural chicoric acid extract (NCRAE) of chicory (Cichorium intybus L.) for an anti-diabetic effect,” Journal of Ethnopharmacology, vol. 215, pp. 241–248, 2018.

[20] N. Ziamajidi, S. Khaghani, G. Hassanzadeh et al., “Amelioration by chicory seed extract of diabetes- and oleic acid-induced non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) via modulation of PPARα and SREBP-1,” Food and Chemical Toxicology, vol. 58, pp. 198–209, 2013.

[21] J. Guo, X. Han, H. Tan, W. Huang, Y. You, and J. Zhan, “Blueberry extract improves obesity through regulation of the gut microbiota and bile acids via pathways involving FXR and TGR5,” iScience, vol. 19, pp. 670–690, 2019.

[22] W. Li, K. Zhang, and H. Yang, “Pectin alleviates high fat (lard) diet-induced nonalcoholic fatty liver disease in mice: possible role of short-chain fatty acids and gut microbiota regulated by pectin,” Journal of Agricultural and Food Chemistry, vol. 66, no. 30, pp. 8015–8025, 2018.

[23] J. T. Haas, S. Francque, and B. Staels, “Pathophysiology and mechanisms of nonalcoholic fatty liver disease,” Annual Review of Physiology, vol. 78, no. 1, pp. 181–205, 2016.

[24] B. Xu, M. Jiang, Y. Chu et al., “Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in

Oxidative Medicine and Cellular Longevity
humans and mice,” *Journal of Hepatology*, vol. 68, no. 4, pp. 773–782, 2018.

[25] S. K. Das, W. S. Chu, A. K. Mondal et al., “Effect of pioglitazone treatment on endoplasmic reticulum stress response in human adipose in palmitate-induced stress in human liver and adipose cell lines,” *American Journal of Physiology-Endocrinology and Metabolism*, vol. 295, no. 2, pp. E393–E400, 2008.

[26] S. H. Bae, S. H. Sung, S. Y. Oh et al., “Sestrins activate Nrf2 by promoting p62-dependent autophagic degradation of Keap1 and prevent oxidative liver damage,” *Cell Metabolism*, vol. 17, no. 1, pp. 73–84, 2013.

[27] S. Herzig and R. J. Shaw, “AMPK: guardian of metabolism and mitochondrial homeostasis,” *Nature Reviews Molecular Cell Biology*, vol. 19, no. 2, pp. 121–135, 2018.

[28] D. G. Hardie, B. E. Schaffer, and A. Brunet, “AMPK: an energy-sensing pathway with multiple inputs and outputs,” *Trends in Cell Biology*, vol. 26, no. 3, pp. 190–201, 2016.

[29] J. Aron-Wisnesky, C. Vigniotti, J. Wijes et al., “Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders,” *Nature Reviews Gastroenterology & Hepatology*, vol. 17, no. 5, pp. 279–297, 2020.

[30] D. Garcia and R. J. Shaw, “AMPK: mechanisms of cellular energy sensing and restoration of metabolic balance,” *Molecular Cell*, vol. 66, no. 6, pp. 789–800, 2017.

[31] M. López, “EJE PRIZE 2017: hypothalamic AMPK: a golden target against obesity?,” *European Journal of Endocrinology*, vol. 176, no. 5, pp. R235–R246, 2017.

[32] R. M. Esquejo, C. T. Salatto, J. Delmore et al., “Activation of liver AMPK with PF-06490577 corrects NAFLD and lowers cholesterol in rodent and primate preclinical models,” *EBio-Medicine*, vol. 31, pp. 122–132, 2018.

[33] A. P. Gupta, P. Singh, R. Garg et al., “Pancrestatin inhibitor activates AMPK pathway via GRP78 and ameliorates dexamethasone induced fatty liver disease in C57BL/6 mice,” *Biomedicine & Pharmacotherapy*, vol. 116, article 108959, 2019.

[34] J. Kim, G. Yang, Y. Kim, J. Kim, and J. Ha, “AMPK activators: mechanisms of action and physiological activities,” *Experimental & Molecular Medicine*, vol. 48, no. 4, article e224, 2016.

[35] R. Guo, B. Zhao, Y. Wang et al., “Cichoric acid prevents free-fatty-acid-induced lipid metabolism disorders via regulating Bmal1 in HepG2 cells,” *Journal of Agricultural and Food Chemistry*, vol. 66, no. 37, pp. 9667–9678, 2018.

[36] S. Satapati, B. Kucejova, J. A. G. Duarte et al., “Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver,” *The Journal of Clinical Investigation*, vol. 125, no. 12, pp. 4447–4462, 2015.

[37] X. Feng, W. Yu, X. Li et al., “Apigenin, a modulator of PPARγ, attenuates HFD-induced NAFLD by regulating hepatocyte lipid metabolism and oxidative stress via Nrf2 activation,” *Biochemical Pharmacology*, vol. 136, pp. 136–149, 2017.

[38] A. K. S. Silva and C. A. Peixoto, “Role of peroxisome proliferator-activated receptors in non-alcoholic fatty liver disease inflammation,” *Cellular and Molecular Life Sciences*, vol. 75, no. 16, pp. 2951–2961, 2018.

[39] C. Mo, L. Wang, J. Zhang et al., “The crosstalk between Nrf2 and AMPK signal pathways is important for the anti-inflammatory effect of berberine in LPS-stimulated macrophages and endotoxin-shocked mice,” *Antioxidants & Redox Signaling*, vol. 20, no. 4, pp. 574–588, 2014.

[40] D. Liu, Z. Ma, S. Di et al., “AMPK/PGC1α activation by melatonin attenuates acute doxorubicin cardiotoxicity via alleviating mitochondrial oxidative damage and apoptosis,” *Free Radical Biology & Medicine*, vol. 129, pp. 59–72, 2018.

[41] X. Han, H. Tai, X. Wang et al., “AMPK activation protects cells from oxidative stress-induced senescence via autophagic flux restoration and intracellular NAD(+) elevation,” *Aging Cell*, vol. 15, no. 3, pp. 416–427, 2016.

[42] Q. Liu, Y. Chen, C. Shen et al., “Chicoric acid supplementation prevents systemic inflammation-induced memory impairment and amyloidogenesis via inhibition of NF-κB,” *The FASEB Journal*, vol. 31, no. 4, pp. 1494–1507, 2016.

[43] M. Yamamoto, T. W. Kessler, and H. Motohashi, “The KEAP1-NRF2 system: a thiol-based sensor-effector apparatus for maintaining redox homeostasis,” *Physiological Reviews*, vol. 98, no. 3, pp. 1169–1203, 2018.

[44] E. H. Kobayashi, T. Suzuki, R. Funaya et al., “Nrf2 suppresses macrophage inflammatory response by blocking pro-inflammatory cytokine transcription,” *Nature Communications*, vol. 7, no. 1, article 11624, 2016.

[45] J. D. Belcher, C. Chen, J. Nguyen et al., “Control of oxidative stress and inflammation in sickle cell disease with the Nrf2 activator dimethyl fumarate,” *Antioxidants & Redox Signaling*, vol. 26, no. 4, pp. 748–762, 2017.

[46] P. C. Shimp, V. R. More, M. Paranipe et al., “Hepatic lipid accumulation and Nrf2 expression following perinatal and peripubertal exposure to bisphenol A in a mouse model of nonalcoholic liver disease,” *Environmental Health Perspectives*, vol. 125, no. 8, article 087005, 2017.

[47] L. Guariguata, “Contribute data to the 6th edition of the IDF Diabetes Atlas,” *Diabetes Research and Clinical Practice*, vol. 100, no. 2, pp. 280–281, 2013.

[48] P. Ramadori, H. Drescher, S. Erschfeld et al., “Hepatocyte-specific Keap1 deletion reduces liver steatosis but not inflammation during non-alcoholic steatohepatitis development,” *Free Radical Biology & Medicine*, vol. 91, pp. 114–126, 2016.

[49] R. S. Sharma, D. J. Harrison, D. Kiselevski et al., “Experimental nonalcoholic steatohepatitis and liver fibrosis are ameliorated by pharmacologic activation of Nrf2 (NF-E2 p45-related factor 2),” *Cellular and Molecular Gastroenterology and Hepatology*, vol. 5, no. 3, pp. 367–398, 2018.

[50] S. Chowdhry, M. H. Nazmy, P. J. Meakin et al., “Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis,” *Free Radical Biology & Medicine*, vol. 48, no. 2, pp. 357–371, 2010.

[51] Y. Wang, Y. Huang, Y. Xu et al., “A dual AMPK/Nrf2 activator reduces brain inflammation after stroke by enhancing microglia M2 polarization,” *Antioxidants & Redox Signaling*, vol. 28, no. 2, pp. 141–163, 2018.

[52] Z. Wang, Z. Chen, Z. Jiang et al., “Cordycepin prevents radiation ulcer by inhibiting cell senescence via Nrf2 and AMPK in rodents,” *Nature Communications*, vol. 10, no. 1, p. 2538, 2019.

[53] H. Tilg and A. R. Moschen, “Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis,” *Hepatology*, vol. 52, no. 5, pp. 1836–1846, 2010.

[54] A. R. Mridha, A. Wree, A. A. B. Robertson et al., “NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice,” *Journal of Hepatology*, vol. 66, no. 5, pp. 1037–1046, 2017.

[55] T. Zhang, J. Hu, X. Wang et al., “MicroRNA-378 promotes hepatic inflammation and fibrosis via modulation of the NF-
xβ-TNFα pathway,” *Journal of Hepatology*, vol. 70, no. 1, pp. 87–96, 2019.

[56] C. X. Li, J. G. Gao, X. Y. Wan et al., “Allyl isothiocyanate ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease via the Sirt1/AMPK and NF-κB signaling pathways,” *World Journal of Gastroenterology*, vol. 25, no. 34, pp. 5120–5133, 2019.

[57] Z. Darabi, M. Darand, Z. Yari et al., “Inflammatory markers response to citrulline supplementation in patients with nonalcoholic fatty liver disease: a randomized, double blind, placebo-controlled, clinical trial,” *BMC Research Notes*, vol. 12, no. 1, p. 89, 2019.

[58] A. Salminen and K. Kaarniranta, “AMP-activated protein kinase (AMPK) controls the aging process via an integrated signaling network,” *Aging Research Reviews*, vol. 11, no. 2, pp. 230–241, 2012.

[59] H. J. Flint, K. P. Scott, P. Louis, and S. H. Duncan, “The role of the gut microbiota in nutrition and health,” *Gastroenterology & Hepatology*, vol. 9, no. 10, pp. 577–589, 2012.

[60] W. Tang, X. Yao, F. Xia et al., “Modulation of the gut microbiota in rats by Hugan Qingzhi tablets during the treatment of high-fat-diet-induced nonalcoholic fatty liver disease,” *Oxidative Medicine and Cellular Longevity*, vol. 2018, Article ID 7261619, 14 pages, 2018.

[61] L. C. Kong, P. H. Wullemin, J. P. Bastard et al., “Insulin resistance and inflammation predict kinetic body weight changes in response to dietary weight loss and maintenance in overweight and obese subjects by using a Bayesian network approach,” *The Journal of Clinical Nutrition*, vol. 98, no. 6, pp. 1385–1394, 2013.

[62] M. Raman, I. Ahmed, P. M. Gillevet et al., “Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease,” *Clinical Gastroenterology and Hepatology*, vol. 11, no. 7, pp. 868–875.e3, 2013.

[63] Y. F. Bai, S. W. Wang, X. X. Wang et al., “The flavonoid-rich Quzhou Fructus Aurantii extract modulates gut microbiota and prevents obesity in high-fat diet-fed mice,” *Nutrition & Diabetes*, vol. 9, no. 1, p. 30, 2019.

[64] E. Org, B. W. Parks, J. W. J. Joo et al., “Genetic and environmental control of host-gut microbiota interactions,” *Genome Research*, vol. 25, no. 10, pp. 1558–1569, 2015.

[65] J. Boursier, O. Mueller, M. Barret et al., “The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota,” *Hepatology*, vol. 63, no. 3, pp. 764–775, 2016.

[66] W. L. Guo, Y. Y. Pan, L. Li, T. T. Li, B. Liu, and X. C. Lv, “Ethanol extract of Ganoderma lucidum ameliorates lipid metabolic disorders and modulates the gut microbiota composition in high-fat diet fed rats,” *Food & Function*, vol. 9, no. 6, pp. 3419–3431, 2018.

[67] H. Ma, B. Zhang, Y. Hu et al., “Correlation analysis of intestinal redox state with the gut microbiota reveals the positive intervention of tea polyphenols on hyperlipidemia in high fat diet fed mice,” *Journal of Agricultural and Food Chemistry*, vol. 67, no. 26, pp. 7325–7335, 2019.

[68] X. Wei, J. Tao, S. Xiao et al., “Xiexin Tang improves the symptom of type 2 diabetic rats by modulation of the gut microbiota,” *Scientific Reports*, vol. 8, no. 1, article 3685, 2018.

[69] M. Kim, G. Yoo, A. Randy, H. S. Kim, and C. W. Nho, “Chicoric acid attenuate a nonalcoholic steatohepatitis by inhibiting key regulators of lipid metabolism, fibrosis, oxidation, and inflammation in mice with methionine and choline deficiency,” *Molecular Nutrition & Food Research*, vol. 61, no. 5, 2017.

[70] H. Xiao, G. Xie, J. Wang et al., “Chicoric acid prevents obesity by attenuating hepatic steatosis, inflammation and oxidative stress in high-fat diet-fed mice,” *Food Research International*, vol. 54, no. 1, pp. 345–353, 2013.

[71] M. Mohammadi, R. Abbassalipourkhah, and N. Ziamajdi, “Fish oil and chicoric acid combination protects better against palmitate-induced lipid accumulation via regulating AMPK-mediated SREBP-1/FAS and PPARα/UCP2 pathways,” *Archives of Physiology and Biochemistry*, vol. 11, pp. 1–9, 2020.

[72] T. Jian, X. Ao, Y. Wu et al., “Total sesquiterpene glycosides from loquat (Eriobotrya japonica) leaf alleviate high-fat diet induced non-alcoholic fatty liver disease through cytochrome P450 2E1 inhibition,” *Biomedicine & Pharmacotherapy*, vol. 91, pp. 229–237, 2017.

[73] Q. Ma, Y. Cui, S. Xu, Y. Zhao, H. Yuan, and G. Piao, “Synergistic inhibitory effects of acacetin and 11 other flavonoids isolated from Artemisia sacrorum on lipid accumulation in 3T3-L1 cells,” *Journal of Agricultural and Food Chemistry*, vol. 66, no. 49, pp. 12931–12940, 2018.

[74] J. Zheng, J. Zhang, Y. Guo et al., “Improvement on metabolic syndrome in high fat diet-induced obese mice through modulation of gut microbiota by Sanguayin decocation,” *Journal of Ethnopharmacology*, vol. 246, article 112225, 2020.